---
title: "Vir Biotechnology names Brent Sabatini interim principal financial officer as CFO exits"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293757111.md"
description: "Vir Biotechnology appointed Brent Sabatini as interim principal financial officer effective July 23, following the departure of CFO Jason O’Byrne. Sabatini, currently senior vice president and chief accounting officer, will lead the search for a permanent CFO while supporting the transition through August 3."
datetime: "2026-07-24T12:30:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293757111.md)
  - [en](https://longbridge.com/en/news/293757111.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293757111.md)
---

# Vir Biotechnology names Brent Sabatini interim principal financial officer as CFO exits

-   Vir Biotechnology named Brent Sabatini interim principal financial officer effective July 23. \* Jason O’Byrne will depart to pursue another opportunity, staying through August 3 to support the transition. \* Sabatini has served as senior vice president and chief accounting officer since February 2023. \* He previously led finance at Capsida Biotherapeutics, following roles at Amgen spanning accounting, tax, FP&A. \* A search is underway for a permanent chief financial officer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607240830BIZWIRE\_USPR\_\_\_\_\_20260724\_BW933681) on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VIR.US](https://longbridge.com/en/quote/VIR.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [Vir Biotechnology Announces Chief Financial Officer Transition | VIR Stock News](https://longbridge.com/en/news/293759460.md)
- [Vir Biotechnology, Inc. Stock 12‑Month Price Target Raised to $21.56, Implies 161% Upside](https://longbridge.com/en/news/289425168.md)
- [Vir Biotechnology schedules conference call on second-quarter 2026 results](https://longbridge.com/en/news/293514769.md)
- [Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer | VIR Stock News](https://longbridge.com/en/news/282996089.md)
- [Vir Biotechnology (NASDAQ:VIR) Downgraded to "Sell" Rating by Wall Street Zen](https://longbridge.com/en/news/285797661.md)